AQW 26836/17-22 Written question to the Minister of Health
To ask the Minister of Health whether patients in Northern Ireland will have access to cabotegravir with rilpivirine on the same basis as those in England and Wales, after the National Institute for Health and Care Excellence recommendation on 18 November 2021 of its use for HIV-1 adults.
Asked by Paula Bradshaw MLA on 3 December 2021
- Answered
- Written
- Tabled
- 3 December 2021
- Answer due by
- 20 December 2021
- Answered
- 15 December 202112 days after tabling
- Department
- Department of Health
- Priority question
- No
Answer
My Department has a formal link with NICE under which NICE Technology Appraisals are reviewed locally for their legal and policy applicability here, and where found to be applicable, they are endorsed for implementation within Health and Social Care (HSC).
When the final guidance for this treatment is issued by NICE, my Department will consider it under the usual process for NICE Technology Appraisals as per the guidance set out in circular HSC (SQSD) 2/13.